Exemptia 40mg (Adalimumab)

Contact us for more information
Wishlist Compare

Exemptia 40mg (Adalimumab)

ManufacturerZydusBrand nameExemptiaActive substanceAdalimumabStrength40mgCategoryOsteoporosis - ArthritisManufacturerZydus

Description of Exemptia 40mg (Adalimumab 40mg)

Exemptia 40mg (Adalimumab 40mg) is an anti-rheumatoid arthritis and Ankylosing spondylitis. Exemptia 40mg (Adalimumab 40mg) is used alone or combined with methotrexate. Exemptia 40mg (Adalimumab 40mg) is a prescription medicine, used by the patients who are all having a valid prescription only under the knowledge of medical practitioner. Exemptia 40mg (Adalimumab 40mg) containing Adalimumab has various activities like; Tumor necrosis factor inhibitory activity Anti-inflammatory activity Immuno suppressive activity Anti-rheumatoid activity (disease modifying) Monoclonal antibody

Medical use /Indication of Exemptia 40mg (Adalimumab 40mg)

Exemptia 40mg (Adalimumab 40mg) injection is used in various conditions like; Rheumatoid arthritis used alone or combine with methotrexate Juvenile idiopathic arthritis in pediatric Psoriasis arthritis Adult crohn’s disease Ankylosing spondylitis Plaque psoriasis Ulcerative colitis All these conditions, Exemptia 40mg (Adalimumab 40mg) are used to reduce the symptoms and provide better heal.

Mechanism of Action Exemptia 40mg (Adalimumab 40mg)

Exemptia 40mg (Adalimumab 40mg) is used to inhibit the tumor necrosis factor which is commonly originating cytidine responsible for inflammatory and immunity response. Rheumatoid arthritis is a condition, in which TNF level gets elevated and accumulated in synovial fluid causes inflammation of joints. Exemptia 40mg (Adalimumab 40mg) containing Adalimumab expels its activity by certainly binds to TNF alpha and complicated in stoppage of association of TNH alpha with its receptors such as p55 & p75 cell surface TNF receptors. Exemptia 40mg (Adalimumab 40mg) is also experienced in lysis of surface TNF expose cells in vitro in the presence of complement.

ADME of Exemptia 40mg (Adalimumab 40mg)

Absorption of Exemptia 40mg (Adalimumab 40mg)

The peak plasma concentration time of Exemptia 40mg (Adalimumab 40mg) is occurs at 131 ± 56 hours and maximum serum concentration reaches as 4.7 ± 1.6mcg/ml The mean bioavailability of Exemptia 40mg (Adalimumab 40mg) is reaches at 64%

Distribution of Exemptia 40mg (Adalimumab 40mg)

The volume of distribution of Exemptia 40mg (Adalimumab 40mg) is 4.7 to 6.0L

Metabolism of Exemptia 40mg (Adalimumab 40mg)

Metabolism of Exemptia 40mg (Adalimumab 40mg) occur hepatically using microsomal enzymes, because of elevation of TNF levels in chronic inflammation which may diminish the production of CYP isoenzymes, the contrariety of TNF activity by Exemptia 40mg (Adalimumab 40mg) may distribute the formation of CYP isoenzymes

Excretion of Exemptia 40mg (Adalimumab 40mg)

The systemic clearance of Adalimumab is relatively occurs as 12ml/hr The mean terminal half life period of Adalimumab is relatively occurs as 2 weeks ranging from 10 to 20 days

Side effects of Exemptia 40mg (Adalimumab 40mg)

Severe infections :

Malignancies, Erythema, Back pain, Hypertension, Thrombocytopenia, Anaphylaxis, Angioneurotic edema, Interstitial lung disease like pulmonary fibrosis, Cutaneous vasculitis, psoriasis, Erythema multiforme, Systemic vasculitis, Itching, Hemorrhage, Pain, swelling, Rash, Pneumonia, Tuberculosis, Lupus like syndrome, Sinusitis, Flu like syndrome, Respiratory tract infection, Abdominal pain, Nausea, Injection site pain, Headache, Lab values abnormalities :

  • Hematuria
  • Elevation of alkaline phosphatase
  • Hypercholesterolemia
  • Hyperlipidaemia.

Precautions of Exemptia 40mg (Adalimumab 40mg)

While using Exemptia 40mg (Adalimumab 40mg) some adverse effects occur : Active or latent tuberculosis, Lymphoma and other malignancy, Hepatosplenic T-cell lymphoma, Various viral, fungal & bacterial infections occur, Increased the risk of infections. To reduce these conditions :

Avoid concurrent use of methotrexate with Exemptia 40mg (Adalimumab 40mg) Before initiate the treatment with Exemptia 40mg (Adalimumab 40mg), patients must counsel about the adverse effects acquired by Exemptia 40mg (Adalimumab 40mg) Risk factors :

Viral, fungal or bacterial infections History of patient already having opportunistic infection Exposure of tuberculosis Serious or intermittent infections

Other adverse effects :

Neurological reactions, Hematological problems, HBV reoccurrence. Risk of non-melanoma skin carcinoma :

Discontinuation of treatment with Exemptia 40mg (Adalimumab 40mg) Hepatosplenic T-cell lymphoma in pediatric patients: Stop the therapy immediately Hypersensitivity reactions occurs, to prevent this reactions avoid concomitant use of Exemptia 40mg (Adalimumab 40mg) with other immunosuppressant agents.

Drug interaction of Exemptia 40mg (Adalimumab 40mg)

Avoid the concomitant use of Exemptia 40mg (Adalimumab 40mg) with live vaccines. Anakinra, a interleukin 1 antagonist while combining with Exemptia 40mg (Adalimumab 40mg) causes serious infection associated to anakinra, to avoid this problem concomitant use of Exemptia 40mg (Adalimumab 40mg) with anakinra should not be recommended. Exemptia 40mg (Adalimumab 40mg) concurrently used with methotrexate, in rheumatoid arthritis may causes diminishing apparent clearance of Exemptia 40mg (Adalimumab 40mg).

Contraindication of Exemptia 40mg (Adalimumab 40mg)

Exemptia 40mg (Adalimumab 40mg) has no contraindications Hypersensitivity reactions present, if patients are contraindicated to the ingredient of Exemptia 40mg (Adalimumab 40mg)

Over dosage of Exemptia 40mg (Adalimumab 40mg)

Once over dose occurs in the patients receiving Exemptia 40mg (Adalimumab 40mg), must monitored the signs and manifestation due to overdose of Exemptia 40mg (Adalimumab 40mg). Patient should be provided with safety measures.

Pregnancy & Lactation of Exemptia 40mg (Adalimumab 40mg)

Pregnancy category of Exemptia 40mg (Adalimumab 40mg) is C

Exemptia 40mg (Adalimumab 40mg) is a rational use in pregnancy condition

Exemptia 40mg (Adalimumab 40mg) may have placental transformation, use with caution under the guidance of medical practitioner.

Lactation :

Breast feeding should not be recommended

Dosage of Exemptia 40mg (Adalimumab 40mg)

  • In rheumatoid arthritis, psoriasis arthritis & Ankylosing spondylitis (RA, PA, & AS) : The usual prescribed dosage of Exemptia 40mg (Adalimumab 40mg) for these conditions, 40mg should be given for every other week through subcutaneously.
  • Methotrexate, NSAIDS, glucocorticoid, salicylates, analgesics, or DMARDs may be carrying out during the therapy with Exemptia 40mg (Adalimumab 40mg) if required.
  • In some conditional patients, methotrexate should not be used in combination. In this condition the frequency of dosage of Exemptia 40mg (Adalimumab 40mg) is increases to 40mg for every week.
  • In adult crohn’s : The usual recommended dosage of Exemptia 40mg (Adalimumab 40mg) is 160mg initiate at day 1 (administered as four 40mg in a day or two 40mg per day for two successive days) following with 80mg two weeks later (day 15).
  • Later two weeks, day 29 initiates with maintenance dose of 40mg should be given for every other week.
  • Aminosalicylates, corticosteroids, or Immuno modulatory agents may be used during the therapy with Exemptia 40mg (Adalimumab 40mg)

For pediatrics :

6 years & older : 17kg to less than 40kg: The initial dose is 80mg given subcutaneous on day 1 followed by 40mg two weeks later, then 20mg SC every other week 40kg or greater: The recommended dosage 160mg of Exemptia 40mg (Adalimumab 40mg) should be given subcutaneous on day 1, respectively 80mg SC for two weeks later, then 40mg SC every other week.

In juvenile idiopathic arthritis : The usual recommended dose of Exemptia 40mg (Adalimumab 40mg) is suitable for the age of 4 to 17 years with polyarticular JIA is calculated on the basis of body weight of the patients. 2 years and older pediatric patients Exemptia 40mg (Adalimumab 40mg) is suggested. Methotrexate, NSAIDS, glucocorticoid, salicylates or analgesics may be used in combination.

  • In 10kg to less than 15kg: 10mg dose should be recommended
  • In 15 kg to <30kg: 20mg of dose should be given for every other week
  • ≥30kg: 40mg of dose should be given for every other week In ulcerative colitis: The prescribed dosage of Exemptia 40mg (Adalimumab 40mg) is 160mg initially given at day 1 (administered as four 40mg in a day or two 40mg per day for two successive days) following with 80mg two weeks later (day 15).
  • After two weeks, day 29 starts with continuance dose of 40mg every other week.

Plaque psoriasis : The recommended dosage of Exemptia 40mg (Adalimumab 40mg) is starting with 80mg, which is followed by 40mg for every other week, initiate one week after the initial dose

Storage of Exemptia 40mg (Adalimumab 40mg)

Store the medicine in refrigerated at 36℉ to 46℉ (2℃ to 8℃). Do not freeze the medicine. Discard the not used medicine within 14 days period.  Store only in original container. While travelling store the room temperature at max 77℉ up to 14 days.

Missed dose of Exemptia 40mg (Adalimumab 40mg)

Exemptia 40mg (Adalimumab 40mg) is used by the patients having serious rheumatoid arthritis, no self medication occur. If patient fail to take the dose of Exemptia 40mg (Adalimumab 40mg) must consult with physician and follow the instruction given by medical adviser or skip the missed dose and follow the regular dosing schedule.

Brand name:
Active substance:
Osteoporosis - Arthritis
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India